CTLA4 and neoplasm: For instance, in a mouse model of PDAC, the use of an anti-CSF1-R antibody in combination with antagonists of PD-1 and CTLA-4 enhanced antigen presentation and productive anti-tumor T cell responses leading to tumor regressions [150].